Non-interventional study. Data obtained by patient chart reviews. Retrospective analysis of progression free survival, time to treatment failure and overall survival in a national cohort of patients with metastatic renal cell carcinoma treated in Denmark from 2006-2010 Safety, prognostic factors, predictive factors and co-morbidity assessed by Charlson Comorbidity Index. The following drugs will be evaluated: Sunitinib, Sorafenib, Temsirolimus, Everolimus, Aldesleukin, Interferon-alfa-2b.
No sampling. All eligible patients will be included.
Study Type
OBSERVATIONAL
Enrollment
1,073
Non-interventional (retrospective chart reviews)
University of Copenhagen Herlev Hospital
Herlev, Denmark
Overall survival from initiation of first systemic anticancer therapy
Time frame: 8 months
Progression free survival from initiation of each systemic anticancer therapy separately
Time frame: 8 months
Time to treatment failure from initiation of each systemic anticancer therapy separately
Time frame: 8 months
Prognostic factors at baseline associated with efficacy (PFS) of each systemic anticancer therapy and overall survival
Time frame: 8 months
Serious Adverse Events: Defined as AEs leading to dose adjustment, treatment interruption/ cessation or death.
Time frame: 8 months
Predictive factors
Time frame: 8 months
Co-morbidity assessed by Charlson Comorbidity Index
Time frame: 8 months
Combined PFS and OS on sequential treatment
Time frame: 8 months
Assessment of first line immunotherapy´s effect on second line targeted therapy
Time frame: 8 months
Assessment of prognostic factors and overall survival for patients not receiving systemic therapy
Time frame: 8 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.